Cabaletta Bio, Inc. (CABA): Total Assets
$165.08M
As of 2025-12-31
$256.73M
As of 2026-06-30
+12.2%
3-year compound annual growth
+7.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $165.08M | -10.8% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $185.05M | -27.0% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $253.65M | +116.9% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $116.97M | -7.4% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $126.34M | +10.1% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $114.72M | -18.9% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $141.47M | +314.0% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $34.17M | n/a | 2020-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $165.08M | -10.8% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $169.43M | -7.2% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $172.81M | +291.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $152.98M | +860.8% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $181.20M | +83.8% |
Compare CABA, AURA, SABS, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗